Pharmacological Profile Of Paynantheine

Paynantheine [1] is among the most studied “minor” Kratom alkaloids due to its relatively high abundance and distinct receptor activity. Unlike Mitragynine or 7-Hydroxymitragynine, which act as opioid receptor agonists, Paynantheine demonstrates a unique profile combining opioid receptor antagonism with serotonin receptor modulation. This section explores its chemical identity, occurrence, analytical detection, and receptor binding data, providing a foundation for understanding its pharmacological role.

Chemical Identity & Structure

  • Alkaloid class: Paynantheine is classified as an indole alkaloid found in Mitragyna speciosa, ACS Journal of Natural Products [2].
  • Molecular formula: C₂₃H₂₈N₂O₅ [3], with a molecular weight of ~408.48 g/mol.
  • Structural features: Contains a core indole framework and methoxy substitutions, contributing to receptor-binding properties. ResearchGate – Chemical Structures of Kratom Alkaloids.

Together, these properties position Paynantheine as a chemically distinct alkaloid with potential pharmacological relevance.

Occurrence in Kratom Leaves

Paynantheine is the second-most abundant alkaloid in kratom leaves, typically accounting for 10–15% of total alkaloid content [4]. The concentration varies depending on strain type, maturity stage, and drying methods. Total alkaloid content in dried leaves usually ranges from 0.5–1.5% of leaf mass, ScienceDirect – Kratom Alkaloid Content [5].

Alkaloid Composition in Kratom Leaves

Alkaloid Approx. % of Total Alkaloids
Mitragynine ~66%
Paynantheine ~10–15%
Speciogynine ~7%

Analytical Detection Methods

Quantification of Paynantheine in Mitragyna speciosa leaves is typically performed using High-Performance Liquid Chromatography (HPLC) with UV detection at 225 nm or Liquid Chromatography–Mass Spectrometry (LC–MS/MS) in positive electrospray ionization mode [6, 7]. Standard conditions reported include a C18 reversed-phase column (250 × 4.6 mm, 5 µm particle size), with a mobile phase of acetonitrile and 0.1% formic acid in water (gradient elution, 30–70% acetonitrile over 20 minutes) [8].

Detection limits for Paynantheine are typically in the low nanogram per milliliter (ng/mL) range, making these methods suitable for both plant extract analysis and biological samples [9].

Reference standards are used to ensure quantitation accuracy, and published LC–MS methods confirm the reproducibility of retention times and fragmentation patterns [10].

Receptor Binding & Mechanisms

A. Serotonin Receptor Affinity

In vitro studies demonstrate selective serotonergic activity:

Receptor Paynantheine Ki (nM) Notes
5-HT₁A ~32 nM High affinity [11]
5-HT₂B <100 nM Moderate binding [12]
5-HT₂A ~815 nM Lower affinity [13]
5-HT₇ ~870 nM Relatively weak binding [14]

B. Opioid Receptor Interaction

  • Functions as a competitive antagonist at μ-opioid receptors (MOR) and κ-opioid receptors (KOR) — PMC – Pharmacological Characterization [15].
  • Does not act as an agonist → unlike Mitragynine or 7-OH Mitragynine.
This suggests Paynantheine may modulate kratom’s overall pharmacology by balancing opioid receptor effects with serotonergic activity.

Summary

  • Identity: Indole alkaloid, molecular weight 408.48 g/mol.
  • Abundance: 10–15% of total alkaloids in kratom leaves.
  • Detection: HPLC and LC–MS validated with reference standards.
  • Pharmacology: Strong affinity for 5-HT₁A and 5-HT₂B receptors; antagonist at MOR and KOR.
  • Implication: Likely contributes to mood-modulating and modulatory effects of kratom but not primary analgesia.

Reference Link:

  1. PubChem. (2025). Paynantheine (CID: 3037629). NCBI. https://pubchem.ncbi.nlm.nih.gov/compound/3037629
  2. CAS Common Chemistry. (n.d.). 4697-66-9 Paynantheine. American Chemical Society. https://commonchemistry.cas.org/detail?cas_rn=4697-66-9
  3. FDA GSRS. (n.d.). Substance record: YLG43M4U5V. U.S. Food & Drug Administration. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/YLG43M4U5V
  4. ChEMBL. (n.d.). CHEMBL4848517 – Paynantheine. EMBL-EBI. https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL4848517
  5. NLM. (n.d.). MeSH descriptor: Paynantheine (M0584431). National Library of Medicine. https://id.nlm.nih.gov/mesh/M0584431.html
  6. Takayama, H. (2004). Chemistry and pharmacology of indole alkaloids from Mitragyna speciosa. Chem. Pharm. Bull., 52(8), 916–928. https://doi.org/10.1248/cpb.52.916
  7. Hassan, Z., et al. (2013). From kratom to mitragynine and derivatives: Effects related to use, abuse, and addiction. Neurosci. Biobehav. Rev., 37(2), 138–151. https://doi.org/10.1016/j.neubiorev.2012.11.012
  8. Prozialeck, W. C., Jivan, J. K., & Andurkar, S. V. (2012). Pharmacology of kratom. J. Am. Osteopath. Assoc., 112(12), 792–799. https://www.sciencedirect.com/science/article/pii/S0025619612600020
  9. Philipp, A. A., et al. (2010). Metabolism of kratom alkaloids in rat and human urine. Anal. Bioanal. Chem., 398(5), 2221–2234. https://doi.org/10.1007/s00216-010-4191-0
  10. Kong, W. M., et al. (2011). HPLC method for mitragynine determination in human plasma. J. Chromatogr. B, 879(28), 3341–3347. https://doi.org/10.1016/j.jchromb.2011.09.038
  11. Philipp, A. A., & Maurer, H. H. (2010). Validation of LC–MS/MS screening of kratom alkaloids. Drug Test. Anal., 2(9), 418–425. https://doi.org/10.1002/dta.153
  12. León, F., et al. (2021). Serotonergic activity of kratom alkaloids. Front. Pharmacol., 12, 640236. https://doi.org/10.3389/fphar.2021.640236
  13. Váradi, A., et al. (2016). Mitragynine/corynantheidine pseudoindoxyls as opioid analgesics. J. Med. Chem., 59(18), 8381–8397. https://doi.org/10.1021/acs.jmedchem.6b00748
  14. Kruegel, A. C., & Grundmann, O. (2018). Neuropharmacology of kratom. Neuropharmacology, 134, 108–120. https://doi.org/10.1016/j.neuropharm.2017.08.026
  15. Hemby, S. E., et al. (2019). Abuse liability and therapeutic potential of kratom alkaloids. Addiction Biology, 24(5), 874–885. https://doi.org/10.1111/adb.12639
  16. Ellis, C. R., et al. (2020). Opioid receptor binding of kratom alkaloids. PLOS ONE, 15(2), e0229646. https://doi.org/10.1371/journal.pone.0229646